Genomic analysis of normal tissues in children with cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to utilize next generation sequencing techniques to identify germline mutations in cancer predisposition genes among pediatric oncology patients. By analyzing normal tissue samples alongside tumor samples, the researchers will correlate genetic findings with clinical outcomes and treatment responses. The study also seeks to understand patient and parent perceptions of genomic testing and the impact of these results on their understanding of cancer risk and treatment options. The ultimate goal is to enhance personalized cancer treatment and prevention strategies for children.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* St. Jude patients prospectively identified at the time of study activation with a diagnosed solid or liquid tumor (benign or malignant).
* Adequate tissue must be available (e.g. sufficient germline and/or tumor tissue, from which \>1 µg DNA and \>0.1 µg RNA must be isolated). Patients who have no tumor tissue available may enroll using only germline sample.

Exclusion Criteria:

* Past history of hematopoietic stem cell transplantation (or other condition that would result in hematopoietic cell DNA failing to match host tissue DNA).
* Tumor or germline tissue not meeting the criteria listed above.
* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
* Participants who are unable to read, write or converse fluently in English or Spanish will be excluded from Prespecified Objectives 3 and 4.

Where it's running

• St. Jude Children's Research Hospital
  Memphis, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Kim E. Nichols, MD — St. Jude Children's Research Hospital
• Study coordinator: Kim E. Nichols, MD
• Email: referralinfo@stjude.org
• Phone: 888-226-4343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mirdametinib for people with central nervous system tumors

  This trial tests whether mirdametinib is safe and can help adults with central nervous system tumors, including glioma and neurohistiocytosis.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07539441

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Evaluating ICP-723 for advanced solid tumors and CNS tumors with NTRK fusions

  This study is testing a new drug called ICP-723 to see if it can help people with advanced solid tumors or brain tumors that have specific gene changes.

  Recruiting Phase 1/2 Beijing InnoCare Pharma Tech Co., Ltd. · Guangzhou, Guangdong · NCT05745623

• Personalized DNA vaccine for pediatric patients with recurrent brain tumors

  This study is testing a personalized DNA vaccine to see if it can improve treatment for young people aged 12 to 25 with recurring brain tumors.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT03988283

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.